These studies have collectively demonstrated that loss of NKG7 impairs both NK and CD8+ T cell-mediated anti-tumor control in vivo and may be important for effective CD8+ T cell responses following immune checkpoint blockade in both mouse and human models (20, 21). The gene discussed is NKG7; the disease is neoplasm.